Regulatory inspections — pre-approval and routine — are critical checkpoints in pharmaceutical product lifecycle management. For M.Pharm students, understanding inspection types, regulatory expectations, documentation requirements and common findings helps bridge theory with real-world compliance. This blog offers focused multiple-choice questions with answers to deepen your knowledge about inspection objectives, inspector authority, data integrity principles, sampling, responses to observations (e.g., Form 483), CAPA, and differences between pre-approval and routine GMP inspections. These MCQs are designed to reinforce practical skills needed for inspection readiness, effective documentation practices and preparing robust responses that protect product quality and patient safety.
Q1. What is the primary objective of a pre-approval inspection (PAI)?
- To verify that the manufacturing facility and associated processes comply with regulatory requirements and support the safety and effectiveness data submitted in the marketing application
- To audit the company’s financial records related to product development
- To train company staff on regulatory writing and submission preparation
- To only check product labeling and marketing claims
Correct Answer: To verify that the manufacturing facility and associated processes comply with regulatory requirements and support the safety and effectiveness data submitted in the marketing application
Q2. Who typically conducts a pre-approval inspection for a drug marketed in a particular country?
- Inspectors from the foreign regulatory authority responsible for marketing approval in that country
- Only internal QA auditors from the sponsor company
- Independent commercial consultants hired by the manufacturer
- Representatives from the contract research organization (CRO) involved in clinical trials
Correct Answer: Inspectors from the foreign regulatory authority responsible for marketing approval in that country
Q3. What is the key difference between a pre-approval inspection and a routine GMP inspection?
- PAI focuses on verification of data supporting the application and readiness for approval; routine inspections focus on ongoing compliance with cGMP and quality systems
- PAI only inspects marketing materials while routine inspection checks production equipment
- PAI is always announced while routine inspections are always unannounced
- There is no difference; both are identical in scope and purpose
Correct Answer: PAI focuses on verification of data supporting the application and readiness for approval; routine inspections focus on ongoing compliance with cGMP and quality systems
Q4. What does an FDA Form 483 represent?
- A list of inspectional observations documented by FDA investigators at the conclusion of an inspection
- A final enforcement action that immediately closes the facility
- A marketing authorization approval form
- An internal company checklist used for mock audits
Correct Answer: A list of inspectional observations documented by FDA investigators at the conclusion of an inspection
Q5. What is the typical timeframe the FDA expects a company to provide a written response to a Form 483?
- 15 business days
- 48 hours
- 90 calendar days
- One year
Correct Answer: 15 business days
Q6. Which advantage is most associated with remote/virtual regulatory inspections?
- Enables offsite review of records and electronic data which can speed inspection scheduling and allow targeted evidence review without inspector travel
- Completely replaces on-site verification of physical processes and equipment
- Prevents inspectors from reviewing any original records
- Removes the need for companies to maintain physical retained samples
Correct Answer: Enables offsite review of records and electronic data which can speed inspection scheduling and allow targeted evidence review without inspector travel
Q7. Which set of attributes correctly represents the ALCOA principles of data integrity?
- Attributable, Legible, Contemporaneous, Original, Accurate
- Accessible, Logical, Compliant, Organized, Archived
- Available, Legally Verified, Controlled, Observed, Authenticated
- Accountable, Locked, Complete, Obvious, Audited
Correct Answer: Attributable, Legible, Contemporaneous, Original, Accurate
Q8. During an on-site inspection, what samples may inspectors collect for independent testing?
- Retained samples, in-market samples, labeling samples and relevant laboratory samples as permitted by regulation
- Only finished product samples that have been sold to patients
- Only raw materials from the supplier’s facility
- Inspectors are not permitted to collect any physical samples
Correct Answer: Retained samples, in-market samples, labeling samples and relevant laboratory samples as permitted by regulation
Q9. What is the most frequently cited type of deficiency observed in routine manufacturing inspections?
- Document control and recordkeeping deficiencies such as incomplete batch records and missing signatures
- Major mechanical failures of all utility systems
- Repeated clinical trial protocol violations
- Financial misreporting related to procurement
Correct Answer: Document control and recordkeeping deficiencies such as incomplete batch records and missing signatures
Q10. What is the primary purpose of a CAPA (Corrective and Preventive Action) program following inspection findings?
- To identify root causes of nonconformities and implement measures to prevent recurrence
- To provide a legal defense for product liability cases
- To calculate production efficiencies for commercial reporting
- To schedule employee vacations to reduce risk
Correct Answer: To identify root causes of nonconformities and implement measures to prevent recurrence
Q11. During an inspection, what is the expected role of the company’s Quality Unit?
- To facilitate the inspection, provide requested records, explain quality systems and coordinate corrective actions
- To act as legal counsel and refuse access to records
- To conduct new product development activities while inspectors are present
- To only supervise production activities and avoid interaction with inspectors
Correct Answer: To facilitate the inspection, provide requested records, explain quality systems and coordinate corrective actions
Q12. Under what circumstance would a regulatory authority typically schedule a re-inspection?
- When significant deficiencies were identified and initial corrections were inadequate or unverified
- Only when the company requests additional training from regulators
- Immediately after a successful product approval without prior findings
- For routine financial audits unrelated to GMP
Correct Answer: When significant deficiencies were identified and initial corrections were inadequate or unverified
Q13. What does issuance of a regulatory warning letter usually indicate?
- There are significant violations requiring corrective action and public notification; failure to respond adequately may lead to enforcement
- The facility has been granted expedited approval for a new product
- The inspection was purely educational with no findings
- The company will receive financial incentives for quality improvements
Correct Answer: There are significant violations requiring corrective action and public notification; failure to respond adequately may lead to enforcement
Q14. Which action is most effective in preparing a facility for a pre-approval inspection?
- Conducting formal readiness assessments including mock inspections, document completeness checks, and staff interview rehearsals
- Waiting for inspectors to arrive and then compiling documents ad hoc
- Only polishing the manufacturing area but ignoring records and QA systems
- Removing older batch records from the facility to avoid scrutiny
Correct Answer: Conducting formal readiness assessments including mock inspections, document completeness checks, and staff interview rehearsals
Q15. What access do inspectors generally expect regarding electronic systems during an inspection?
- Access to relevant electronic records, audit trails, user access logs and validated system documentation as evidence of data integrity
- Only screenshots of summary reports without audit trail details
- Inspections never include review of electronic systems
- Access only to personal employee emails unrelated to production
Correct Answer: Access to relevant electronic records, audit trails, user access logs and validated system documentation as evidence of data integrity
Q16. If original laboratory raw data are found missing during an inspection, which approach is acceptable?
- Reconstruct the data from validated backups or instrument logs with documented justification, showing why originals are missing and what was done to recover and verify data
- Falsify records to make it appear as if originals were present
- Claim that raw data are proprietary and refuse to produce any evidence
- Ignore the inspector’s inquiry and hope the issue is not pursued
Correct Answer: Reconstruct the data from validated backups or instrument logs with documented justification, showing why originals are missing and what was done to recover and verify data
Q17. What aspects of stability programs are commonly reviewed during inspections?
- Storage conditions, protocol adherence, sample labeling, data integrity, trending and out-of-specification handling
- Only the brand logo printed on stability chambers
- Financial costs associated with long-term stability studies
- Clinical subject stability during trials
Correct Answer: Storage conditions, protocol adherence, sample labeling, data integrity, trending and out-of-specification handling
Q18. Regarding batch release, what is the inspector’s role during an inspection?
- Inspectors review batch records and QA release decisions but do not themselves release product to the market
- Inspectors may directly sign and release batches during the inspection
- Inspectors set the company’s release specifications permanently
- Inspectors are not allowed to review batch documentation
Correct Answer: Inspectors review batch records and QA release decisions but do not themselves release product to the market
Q19. How frequently are routine GMP inspections typically scheduled for established manufacturing facilities?
- On a risk-based schedule, commonly about every 2–3 years for domestic facilities unless risk or prior findings require more frequent oversight
- Once every 20 years regardless of risk
- Monthly for all manufacturing sites without exception
- Never; inspections only occur during pre-approval
Correct Answer: On a risk-based schedule, commonly about every 2–3 years for domestic facilities unless risk or prior findings require more frequent oversight
Q20. What constitutes a best-practice response to a Form 483 observation?
- A timely, well-documented 15-day response describing root cause analysis, specific corrective and preventive actions, implementation timelines and evidence or interim measures
- A generic denial that no issues exist without supporting evidence
- Submission of unrelated marketing materials to distract regulators
- Requesting indefinite delay in responding until market approval is granted
Correct Answer: A timely, well-documented 15-day response describing root cause analysis, specific corrective and preventive actions, implementation timelines and evidence or interim measures
